bioRxivCancer BiologyPreprint
PRC2 Restricts Malignant Peripheral Nerve Sheath Tumorigenesis in a Genetically Engineered Mouse Model of MPNST
Woo Hyun ChoiD, Amish J. PateliD, Makzhuna Khudoynazarova, Sarah WardaiD, Juan YaniD, Dan LiiD, Dana M. Schoeps, Eve FishinevichiD, Mohini R. PachaiiD, Cindy J. LeeiD, Zoe Jacobs, Kae Kristoff, Jessica J. SheriD, Cristina R. AntonescuiD, Yu CheniD, Ping ChiiD
Abstract
Polycomb Repressive Complex 2 (PRC2), which normally regulates transcriptional silencing, chromatin compaction, and stem cell biology, has both oncogenic and tumor suppressor roles in cancer development depending on tumor type. Malignant peripheral nerve sheath tumor (MPNST), characterized by NF1, CDKN2A and PRC2 loss, is an aggressive subtype of sarcoma with poor prognosis and no effective therapy. In high-grade human MPNSTs, inactivating mutations in PRC2 core components SUZ12 or EED are prevalent and contributes to oncogenic transformation and progression of MPNST. How PRC2 inactivation contributes to MPNST pathogenesis, however, remains incompletely understood. Here we show that genetic inactivation of Eed in addition to Nf1 and Cdkn2a in the Schwann-progenitor lineage leads to widespread tumorigenesis within the sciatic nerve compartment of mice. In contrast, loss of Nf1 and Cdkn2a is insufficient to drive tumorigenesis in the sciatic nerve but leads to MPNST development in other anatomic locations with a longer latency. Single-nucleus multiome sequencing of the sciatic nerves revealed that PRC2-loss reprograms Nf1/Cdkn2a-deficient Schwann-lineage cells toward a dedifferentiated, neural crest stem cell-like state that resembles the transcriptomic signatures of human PRC2-loss MPNST. Together, these findings suggest a context-dependent tumor suppressive role for PRC2 within the sciatic nerve and establish a novel mouse model that recapitulates human PRC2-loss MPNST. SIGNIFICANCEWe present a novel genetically engineered mouse model that faithfully recapitulates human PRC2-loss MPNST, enabling mechanistic and preclinical studies of malignant transformation in the context of PRC2 loss.
- organism: mouse
- assay: scRNA-seq
- assay: multiome
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: trajectory inference
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- iPSC-derived NF1-CDKN2A-PRC2 deficient neural crest mimics MPNST glial-to-neuro-mesenchymal transition and uncover new therapeutic opportunities
Itziar Uriarte-Arrazola, Miriam Magallón‐Lorenz, … Eduard Serra·bioRxiv·Aug 13, 2025
- A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor
A. Inoue, L. J. Janke, … X. Cao·bioRxiv·May 3, 2021
- Integrated Proteomic and Epigenomic Analysis Reveals IGF2 as a Vulnerability in PRC2-Deficient Malignant Peripheral Nerve Sheath Tumors
Joanna K. Lempiäinen, Kirill Miachin, … Benjamin A. Garcia·bioRxiv·Nov 5, 2025
- The Cell Surface Proteome of Malignant Peripheral Nerve Sheath Tumors Reveals Therapeutic Targets
Christopher M. Stehn, Liangjun Wang, … David A. Largaespada·Neuro-Oncology AdvancesPeer-reviewed·Jan 1, 2026
- Cross-species Study of Canine and Human Peripheral Nerve Sheath Tumors: Clinical and Molecular Perspectives
Jace P. Landry, Angela D. Bhalla, … Keila E. Torres·bioRxiv·Jul 29, 2026
- Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA
I. Cortes-Ciriano, C. D. Steele, … D. T. Miller·bioRxiv·May 3, 2022